Mindscape Collective is now The Consciousness Library. Same library, new name. You may need to sign in again. About the change
Skip to content

Methoxetamine: A foe or friend?

Chrislean Jun Botanas, June Bryan De la Peña, Hee Jin Kim, Yong Sup Lee, Jae Hoon Cheong

Neurochemistry International January 1, 2019 DOI: 10.1016/j.neuint.2018.10.020 (opens in new tab) via PubMed

Summary

AI-generated from the abstract

Methoxetamine (MXE) is a dissociative drug similar to ketamine and phencyclidine that acts as an NMDA receptor antagonist. While MXE has known abuse liability, can stimulate dopamine in the brain's reward pathway, and has been linked to adverse effects and deaths, recent preclinical studies suggest it also possesses antidepressant and analgesic properties. These potential therapeutic effects are thought to involve the glutamatergic and serotonergic systems. This review compiles evidence on both the harmful effects—toxicity, psychotomimetic effects, and abuse potential—and the promising therapeutic qualities of MXE, discussing the mechanisms that may explain these paradoxical effects.

Study at a glance

Characteristics Review Peer reviewed
Keywords Abuse liability Antidepressant Intoxication Methoxetamine
Key finding MXE has both adverse effects, including abuse liability and toxicity, and potential therapeutic effects, such as antidepressant and analgesic properties, based on preclinical studies.

Abstract

Methoxetamine (MXE) is an N-methyl-D-aspartate (NMDA) receptor antagonist that is chemically and pharmacologically similar to other dissociative substances, such as ketamine and phencyclidine. There are reports on the misuse of MXE, which sometimes resulted in adverse consequences and death. Studies have also shown that MXE has abuse liability and stimulates dopamine neurotransmission in the mesolimbic reward pathway in the brain. These findings have contributed to the negative impression on MXE. However, recent preclinical studies have identified the antidepressant properties of MXE, which are attributed to its ability to affect the glutamatergic and serotonergic systems. MXE is also reported to have analgesic effects. These findings show some of the "redeeming qualities" of MXE and indicate its possible therapeutic uses. In this paper, we have reviewed the findings that provide insights into the adverse and potential therapeutic effects of MXE. We compiled studies on the toxicity, psychotomimetic effects, and abuse liability of MXE, as well as its promising antidepressant and analgesic properties. We also have discussed the mechanism of action that might mediate the somewhat paradoxical effects observed. Importantly, this review provides valuable information on MXE for future research and will enable a better understanding of its psychopharmacological properties and the mechanisms responsible for its unique effects.

Comments

No comments yet.

Log in to comment